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Abstract 
 
Introduction 
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central 
nervous system (CNS), which may have long-term consequences on patients’ quality of 
life. In the majority of MS sufferers, the first presentation is in the form of a clinically 
isolated syndrome (CIS). In this study, we aim to investigate the applicability of serial 
assessment of linear and two-dimensional measures of cerebral atrophy in patients 
presenting with CIS using magnetic resonance imaging (MRI). We will also evaluate the 
relationships of these measures with clinical outcome variables, including conversion to 
MS, annualised relapse rate and disability. 
 
Methods 
MRI and clinical variables from a total of 282 participants with a clinical diagnosis of CIS 
recruited into the Ausimmune study were collated, with 154 participants having complete 
imaging and clinical data at baseline and five-year review. Linear measures of cerebral 
atrophy performed on axial MRI images included: frontal horn width (FHW), intercaudate 
distance (ICD), and third ventricular width (TVW). Midsagittal corpus callosum area (CCA) 
was performed on a subgroup of 143 participants with sagittal MRI acquisitions at both 
time points. Relationships between cerebral atrophy measures and clinical outcome 
variables were assessed.  
 
Results 
Patients who converted to MS by five-year review demonstrated a significantly smaller 
CCA at follow-up (p = 0.007). Greater annualised rate of CCA reduction was associated 
with higher disability scores at five-year review (p = 0.023). None of the linear measures of 
cerebral atrophy differentiated between converters and non-converters to MS.  
 
Discussion 
Two-dimensional measures of cerebral atrophy obtained at baseline may be compared 
with subsequent MRI examinations as a surrogate for neurodegeneration and cerebral 
atrophy in patients presenting with clinically isolated syndrome. This study demonstrates 
an association between CCA and disability in individuals presenting with CIS who convert 
to MS. 
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CHAPTER 1: INTRODUCTION 
 
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the CNS, which 
may have long-term consequences on patients’ quality of life. In patients with longstanding 
MS, reduced brain volume is considered a surrogate marker for neurodegeneration.(1-3) 
In 85% of MS sufferers, the first presentation is in the form of a clinically isolated syndrome 
(CIS).(4)  
 
Neurodegeneration and cerebral atrophy may be present at CIS presentation; however, 
findings among the published literature are inconsistent. To date, no study has 
demonstrated any significant difference in global measures of WM or GM volumes in CIS 
patients. In one investigation, CIS patients had reduced volume of deep grey matter 
structures(5), however these findings have not been replicated by subsequent studies.(6-
10) In the more recent literature, CIS subjects who convert to clinically definite MS have 
been demonstrated to have greater percentage total brain volume change, demonstrated 
through serial volumetric measurement, compared to those who do not.(11, 12)  
 
In addition to being inaccessible for the practicing clinician, it has been suggested that MRI 
cerebral volumetric analysis is inherently flawed, due to inaccurate segmentation of deep 
GM structures(13), and tissue misclassification in subjects with greater lesion burden.(14) 
In this study, we aim to investigate the applicability of serial assessment of linear and two-
dimensional measures in the assessment of cerebral atrophy in patients presenting with 
CIS. We will also evaluate the relationships of these measures with clinical outcome 
variables, including conversion to MS, clinical relapse frequency and disability. 
 
This thesis includes one published paper (Chapter 2), and one accepted for publication 
(Chapter 4). Chapter 4 was written in collaboration with investigators from the Ausimmune 
and AusLong study groups. Dr Steve Simpson Jr contributed for Chapter 4 through 
providing assistance with statistical analysis. Dr Jurgen Fripp contributed to Chapter 4 by 
performing a validation study on a separate cohort of healthy individuals. 
Ausimmune/AusLong investigators Bruce Taylor, Robyn Lucas, Keith Dear and Anne-
Louise Ponsonby performed editing of Chapter 4.   
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CHAPTER 2: LITERATURE REVIEW 
 
Current use of MRI in clinically isolated syndrome 
 
Numerous MRI techniques have previously been investigated as potential tools for 
prediction of future disease and/or morbidity in patients presenting with CIS. The following 
chapter is amended from a published literature review. The prognostic utility of MRI in 
clinically isolated syndrome: a literature review was published in the American Journal of 
Neuroradiology, issue 35, 2015 (Appendix 1). 
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Introduction 
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the CNS, which 
may have long-term consequences on patients’ quality of life. In 85% of MS sufferers, the 
first presentation is in the form of a clinically isolated syndrome (CIS).(4)  
 
MRI has a central role in the investigation of patients presenting with a suspected 
demyelinating illness. In addition to excluding other diseases, MRI allows clinicians to 
observe the pathological processes underpinning the clinical manifestations in-vivo. In 
individuals with established MS, MRI appearances are considered predictive of future 
disability and disease progression. However, the prognostic value of MRI in subjects 
presenting with CIS is less clear. 
 
This review will address whether MRI data from subjects presenting with CIS is predictive 
of future disease and disability. New and emerging MRI technologies will also be reviewed. 
 
Methods 
References were identified by PubMed and MEDLINE searches, conducted between 1993 
and March 2014, with further references also identified from relevant articles. The search 
terms “clinically isolated syndrome”, “CIS”, “first demyelinating event”, “FDE”, “multiple 
sclerosis”, “MS”, “magnetic resonance imaging”, and “MRI” were used. Articles were 
limited to English language. 
 
Studies for inclusion were to meet the following criteria: 1) study must address the ability of 
MRI to predict MS and/or disability in subjects with CIS; 2) MRI must be performed at initial 
presentation; 3) CIS subjects must be statistically analysed separately from other 
phenotypes. The following exclusion criteria were applied: 1) MRI features not included as 
independent or dependent variables in statistical analysis; 2) subject group with single-
category symptomatology only; 3) spinal cord MRI investigation only; 4) paediatric studies. 
 
A single reviewer with experience in research design and methodology performed the 
literature search and collated data. 
 
Definition of CIS 
CIS is defined as a monophasic presentation with suspected underlying inflammatory 
demyelination. Symptoms are typically of rapid onset, and last for more than 24 hours. CIS 
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is divided into four categories, based on whether presentation demonstrates mono- or 
multifocal clinical or MRI features (Table 1).(15) MRI lesions should appear typical for 
demyelination, may be located in the brain or spinal cord, and an alternative diagnosis 
should be considered less likely.(15) 
 
Published rates of conversion from CIS to clinically definite MS (CDMS) differ according to 
length of study follow-up. Five studies were identified in which subjects were followed for 
greater than 6 years. For follow-up of 6.9, 7.2, 7.3, 14.0 and 20.0 years, total conversion 
rates were 48%, 60%, 85%, 68% and 63%, respectively.(16-20) 
 
Table 1: Classes of CIS (Adapted from: Miller DH, et al., 2008(15)) 
Type 1 CIS: clinically monofocal, at least one asymptomatic MRI lesion 
Type 2 CIS: clinically multifocal, at least one asymptomatic MRI lesion 
Type 3 CIS: clinically monofocal, MRI may appear normal; no asymptomatic MRI lesions  
Type 4 CIS: clinically multifocal, MRI may appear normal; no asymptomatic MRI lesions  
Type 5 CIS: no clinical presentation to suggest demyelinating disease, but MRI is suggestive 
 
Conventional MRI 
Conventional MRI has a well-established role in the initial assessment of subjects with 
CIS. The risk of conversion to CDMS is greater in patients presenting with abnormal T2WI. 
50-70% of CIS subjects present with abnormal T2WI.(4) Two studies were identified which 
observed subjects for over 10 years. Fisniku et al followed 107 CIS subjects to 20.2 years; 
82% with abnormal baseline MRI converted to CDMS, compared to 21% with normal 
MRI.(20) In another study, 88% of subjects with abnormal MRI converted by 14 years, 
compared to 19% of those with normal scans.(19)  
 
T2 lesion number at presentation has been associated with increased risk of conversion to 
CDMS.(8, 21-29) However a recent meta-analysis concluded that abnormal T2WI, 
regardless of lesion number, was associated with increased risk of conversion.(30) 
However, the review was limited, with non-uniform definitions of conversion to MS, and 
varied length of follow-up among the included studies. 
 
In addition to T2 lesions, increased risk of conversion to MS is associated with the 
presence of gadolinium (Gd)-enhancing lesions.(8, 21, 25-27, 31-35) Accurate estimation 
of the incidence of Gd-enhancing lesions at CIS presentation is difficult, due to 
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inconsistent administration of contrast across studies. Gd-enhancing lesions may only be 
present in subjects with abnormal T2WI.(21, 36) The presence of at least one Gd-
enhancing lesion is predictive of time to CDMS in monofocal, but not in multifocal, 
presentations.(37) 
 
The prognostic significance of T1 lesions has been infrequently addressed. Summers et al 
found that in addition to Gd-enhancing lesions, T1 lesions were predictive of cognitive 
dysfunction after 7 years.(17) 
 
Few studies have addressed the association between conventional MRI measures and 
disability. A number of disability scales are used in subjects with CIS. The most frequently 
used scale is the expanded disability status scale (EDSS), which primarily assesses 
ambulation.(38) Another scale, the multiple sclerosis functional composite (MSFC), 
addresses cognition in addition to mobility.(39, 40) Baseline T2 lesion number is 
associated with EDSS at long-term follow-up of up to 14 years.(19, 22) A recent study 
found that baseline Gd-enhancing lesion number was predictive of both EDSS and MSFC 
at 6 years. The authors also found that while baseline T2 lesion number was not 
associated with disability, the increase in T2 lesion number over the first year after 
presentation was predictive of EDSS at 6 years.(11) 
 
Similarly to subjects with MS, lesions are primarily distributed around the ventricular 
system in subjects with CIS.(6, 41) The risk of disease progression is associated with 
lesion location, with periventricular(42), callosal(42, 43) and cerebellar(44) distributions 
being most associated with conversion to CDMS.  
 
Infratentorial lesion location may be associated with increased risk of disease and 
disability.(44, 45) Since infratentorial lesions are likely to affect clinically eloquent areas, 
they may have greater contribution to future disability.(44) However, brainstem syndromes 
are represented infrequently in the literature. In a large multicentre study of 468 CIS 
subjects, infratentorial lesions (including the brainstem and cerebellum) were not 
associated with increased risk of conversion.(25) 
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MRI Volumetrics 
Brain volume measurement is considered a surrogate marker for neurodegeneration in 
patients with MS.(46) It is uncertain whether neurodegeneration is present in subjects with 
CIS.  
 
Techniques for MRI volumetrics may be two- or three-dimensional, and range from fully 
manual to fully automatic. Numerous software packages are available, including Statistical 
Parametric Mapping(47); FreeSurfer(48, 49); and FMRIB Software Library.(50, 51) After 
removing the skull, automated segmentation algorithms are applied to MRI data to obtain 
GM(52), WM(53), CSF and whole brain volumes. In addition to absolute values, volumes 
may be expressed as a fraction of total intracranial volume.  
 
Estimates of baseline lesion volumes are heterogeneous. Mean T2 lesion volume (T2LV) 
has been estimated to be between 2.0ml to 6.2ml(9, 11, 33, 54-57), while T1 lesion 
volume (T1LV) estimates range from 0.4ml to 0.5ml.(11, 56, 57) Gd-enhancing lesion 
volume has been inconsistently reported, due to non-uniform use of contrast. Baseline 
lesion volumes have been noted to differ considerably depending on patient 
symptomatology.(33, 55) 
 
CIS subjects who convert to CDMS demonstrate a greater T2LV at presentation, 
compared to those who do not convert.(8, 11, 24, 34, 58) From multivariate regression 
analysis, Calabrese et al found that baseline T2LV was an independent predictor of 
conversion to MS by 4 years.(7) A study by Paolillo et al, on the other hand, did not 
demonstrate either T1LV or T2LV to be associated with conversion; however, in that study 
follow-up was limited to 18 months.(59) 
 
T2LV is associated with the development of future disability. An early study by Brex et al 
found that baseline T2LV was associated with EDSS at 14 years, with the increase in 
T2LV over the first 5 years also being associated with disability at follow-up.(19) Similarly, 
other studies have found that the rate of increase in T2LV in the first year is associated 
with greater long-term disability.(11, 20) 
 
T1LV may be better suited to the prediction of disability scales other than EDSS. Di Filippo 
et al found that while baseline T1LV was not associated with EDSS, it did correlated with 
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MSFC at 6 years.(11) Another study found that both T1 lesion number and volume were 
predictive of future cognitive dysfunction.(17) 
 
Baseline measures of whole-brain volume have not been consistently demonstrated to 
differentiate CIS subjects from healthy controls, with a number of studies finding no 
significant difference at baseline.(5, 6, 34, 55, 56, 58, 60, 61) These findings are in 
contrast to that of Sbardella et al; however, CIS subjects included in their study had a high 
lesion load (mean T2 lesion number 15.5).(62) To date, no study has demonstrated any 
significant difference in global measures of WM or GM volumes in CIS patients. 
 
In a cross-sectional study, Henry et al reported volume reduction in a number of deep GM 
structures of CIS subjects, compared to controls, including the thalamus and caudate 
nucleus. Although deep GM volumes were not correlated with EDSS, cerebellar volume 
was associated with baseline tests of cerebellar function.(5) In another study, reduced 
thalamic volume in CIS subjects was not retained after correction for multiple 
comparisons.(63) Numerous other authors have since failed to demonstrate any 
convincing GM volume reduction in CIS subjects.(6-10) A recent study of 212 subjects did 
find that increased T2LV was associated with reduced volume of a number of deep GM 
structures; however, the study lacked healthy controls.(5, 55) 
 
A fundamental flaw in regional volumetric analysis is inaccurate segmentation of deep GM 
structures.(13) Greater lesion burden leads to more problems in tissue 
misclassification.(14) More accurate estimation of atrophy is possible when volume 
change is measured directly from serially acquired MRI scans using registration-based 
methods.(13)  
 
SIENA (“Structural Image Evaluation, using Normalisation, of Atrophy”) is a robust, well-
validated tool that uses registration-based methods to estimate percentage brain volume 
change (PBVC) between two time points.(50, 51) While it does not allow estimation of 
regional volumes, SIENA is highly reproducible.(64) Estimates of PBVC range from 
−0.35% to −0.73% per year in CIS subjects.(11, 12, 59, 64) Subjects who convert to 
CDMS have been demonstrated to have greater PBVC than those who do not.(11, 12) 
Kalincik et al, in contrast, found that PBVC was not significantly different in CIS subjects 
who converted. However, in their study all CIS subjects had abnormal T2WI.(34) 
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The corpus callosum is a structure of interest in demyelinating illnesses. In a longitudinal 
study of 24 CIS subjects, Audoin et al found that the midsagittal corpus callosal area was 
significantly reduced at 12 months, when compared to healthy controls. Callosal area also 
correlated with progression in EDSS.(3) More recently, in a larger cohort of 220 CIS 
subjects, change in callosal area in the first 6 months after presentation was predictive of 
conversion to CDMS by 2 years.(34) 
 
Diffusion Tensor Imaging 
DTI allows assessment of the structural integrity of tissues, with water diffusivity being 
affected by various CNS tissue barriers, including microtubules and cell membranes. 
Descriptive parameters include fractional anisotropy (FA), reflective of the fraction of 
anisotropy along one direction, and mean diffusivity (MD) or apparent diffusion coefficient 
(ADC), which is the average diffusion per voxel, regardless of direction. In WM, fibre 
organisation is reflected by the anisotropy, with the quantity of anisotropy being 
augmented by the integrity of surrounding myelin.(65) 
 
While histogram analysis of mean diffusivity has been shown differentiate CIS subjects 
from healthy controls(66), region-of-interest approaches have not.(67) 
 
Using tractography, Pagani et al found that CIS subjects with pyramidal symptoms had 
increased mean diffusivity in the pyramidal tract, compared to both patients without 
symptoms, and control subjects.(68) On the other hand, another study found that CIS 
patients had increased mean diffusivity in all WM tracts.(69) Neither study found a 
difference in baseline fractional anisotropy in CIS subjects.(68, 69) In contrast, another 
study using tract-based spatial statistics (TBSS) demonstrated widespread reduced 
fractional anisotropy in the WM of CIS subjects.(63) Tract-based spatial statistics is a 
recently developed technique that allows analysis of microstructural fibre damage(70), and 
may be more sensitive to detect subtle anisotropy changes. However, while baseline 
fractional anisotropy was correlated with GM atrophy at 1 year in the same cohort, there 
was no association with disability.(63, 71) 
 
Magnetisation Transfer Imaging 
Magnetisation transfer imaging (MTI) measures the transfer of magnetization from 
hydrogen nuclei of water with restricted motion (bound pool), to hydrogen nuclei of freely 
moving water (free pool). This allows imaging of the bound pool, which includes protons in 
  19 
macromolecules, including myelin. The magnetisation transfer ratio (MTR) thus represents 
pathological changes to macromolecules.(72) 
 
Results of studies using MTI have been mixed. Ianucci et al found that the MTR of CIS 
patients differed significantly from healthy controls; however, all patients had ≥4 
lesions.(58) In a large multicentre study, MTR differentiated patients from controls in only 
one of three study centres.(56) Therefore, MTR abnormalities are likely associated with 
increased lesion number at presentation.(60, 73) 
 
MTR has been shown to be predictive of conversion to CDMS(58), and future cognitive 
decline.(74) However, some studies have found conflicting results.(56, 75) Another MTI 
technique, MTR texture analysis, has not been demonstrated to have prognostic utility in 
CIS patients.(16) 
 
MRI Spectroscopy 
N-acetyl-aspartate (NAA) is a metabolite considered to be exclusive to neurons. Wattjes et 
al identified a significant reduction in tNAA (summed NAA and its moeity, N-acetyl-
aspartyl-glutamate) in the normal-appearing WM of CIS subjects compared to healthy 
controls.(76) Subsequent studies have had conflicting results.(42, 77) Other studies have 
found that only those patients with clinical progression demonstrated reduced NAA at 
presentation.(62, 78) 
 
Myo-inositol (mIns, or Ins) is a metabolite primarily concentrated in glial cells. As with NAA, 
studies of this metabolite have demonstrated mixed results. In one study, when CIS 
subjects were compared to controls, baseline Ins of normal-appearing WM discriminated 
only those who went on to covert to CDMS.(78) On the other hand, another study of a 
larger cohort found that Ins concentration was higher across the entire CIS group.(77) 
 
Metabolite concentrations have a temporal evolution after CIS presentation. Audoin et al 
performed serial MRS, with metabolite concentrations measured in the corpus callosum. 
They demonstrated baseline reduced NAA, and increased choline (Cho, associated with 
myelin), both of which normalised by 6 months.(3) In another study, the rate of increase in 
Ins concentration in normal-appearing WM over the first year was predictive of poor 
executive function at 7.2 years.(17) 
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While metabolite concentrations may be associated with long-term cognitive change, no 
single metabolite has demonstrated a correlation with disability, either at baseline or 
follow-up.(17, 77) However, a model combining metabolite concentrations to other MRI 
variables was shown to demonstrate superior utility in predicting disability at one year, 
compared to any variable alone.(62) 
 
Functional MRI 
Functional cortical changes are present from the earliest stages of CIS. Compared to 
healthy controls, CIS subjects demonstrate increased cortical activation in both cerebral 
hemispheres(79, 80), with the extent of activation being related to motor task difficulty.(81) 
Patterns of activation are associated with short-term disease evolution, with converters 
demonstrating recruitment of a more extensive sensorineural network at baseline.(82) In a 
study assessing cognitive changes in CIS, more widespread activation on fMRI was 
associated with improved cognition scores, both at baseline and 1-year follow-up.(83) 
 
Using a novel fMRI technique called dynamic causal modelling (DCM), Rocca et al found 
that CIS subjects had increased interconnectivity between the left and right sensorimotor 
cortex.(84) However, subjects were not followed longitudinally. 
 
A recent study measured the ALFF (amplitude of low frequency alteration) in resting-state 
fMRI. Compared with healthy controls, CIS subjects demonstrated decreased ALFF in 
numerous cerebral regions.(85) In contrast, MS subjects have previously been shown to 
have areas of increased cerebral ALFF.(86) The authors hypothesised that ALFF may 
evolve as time passes from the initial presentation.(85) 
 
MRI Perfusion 
Varga et al quantified cerebral blood flow with MR perfusion in a mixed cohort of subjects 
with CIS and MS. Compared to healthy controls, they found hypoperfusion in the 
periventricular normal-appearing white matter of CIS subjects. However, none of the 
perfusion parameters was associated with disability measures in either subgroup.(87) 
 
Brain Iron Quantification 
T2 hypointensity, attributable to iron deposition, is a frequent finding in subjects with 
MS.(88) In CIS subjects, T2 hypointensity has been identified in the left caudate 
nucleus.(89) Khalil et al used R2* relaxometry to quantify brain iron deposition in a cohort 
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of CIS and MS subjects. Compared to MS subjects, CIS patients had significantly reduced 
R2* values in a number of deep GM regions. While R2* values correlated with regional 
brain volumes, there was no association with disability.(90) In another study, CIS patients 
had significantly reduced R2* values in the basal ganglia and thalamus.(91) However, this 
study was limited, as age was not considered in the methodology, despite control subjects 
being 3 years older than those with CIS.(91) 
 
Hagemeier et al used a SWI phase approach to obtain MP-APT (mean phase of the 
abnormal phase tissue), a metric for quantification of iron levels. Compared with healthy 
controls, CIS subjects had significantly increased abnormal phase and abnormal phase 
volume in a number of deep GM regions. However, iron deposition was noted in the 
absence of any significant volume change.(9) 
 
In addition to R2* relaxometry, Langkammer et al performed quantitative susceptibility 
mapping (QSM) on 26 CIS subjects. QSM detects magnetic charge variations attributable 
not only to iron, but also to myelin. Although R2* relaxometry did not differentiate between 
CIS subjects and controls, QSM revealed abnormality in the caudate, putamen and basal 
ganglia in CIS subjects.(92) In apparent contrast, a recently published study by Quinn et al 
showed that CIS subjects had increased R2* compared to age-matched healthy controls in 
a number of regions, including the medial thalamus and right putamen. Further, thalamic 
R2* relaxometry indices were positively correlated with EDSS (r = 0.47, p = 0.028).(93) 
Apparently conflicting results by these two recently published studies may be attributable 
to differences in image processing techniques. While Langkammer et al calculated the 
mean R2* of segmented cerebral structures, Quinn et al used voxel-wise analysis. 
 
MRI in Clinical Trials 
MRI features have been included as outcome measures in a number of therapeutic trials. 
Treatments tested included: plasma exchange(94), intramuscular interferon beta-1a(95), 
and interferon beta-1b.(96, 97) CIS patients with abnormal baseline T2-weighted MRI are 
ideal candidates to include in therapeutic trials, due to increased risk of conversion to 
MS.(98) 
 
Emerging MRI Technologies 
Multi-component driven equilibrium single pulse observation of T1 and T2 (mcDESPOT) is 
a newly developed MRI technique used to quantify myelin tissue content in vivo.(99) 
  22 
Kitzler et al examined the utility of mcDESPOT for measurement of myelin water fraction 
(MWF) across a range of MS subtypes. In CIS subjects, the total volume of voxels 
demonstrating deficient MWF was statistically significant greater than healthy 
controls.(100) To date, there are no longitudinal studies on CIS subjects using this 
technique. 
 
  23 
Two-dimensional methods of atrophy measurement 
 
Frontal horn width 
Initially investigated in patients with dementia, the greatest transverse width of the frontal 
horns of the lateral ventricles is considered a surrogate marker for frontal brain volume 
reduction.(101) In patients with MS, absolute frontal horn width (FHW) has been measured 
on T2 (102), T1 axial (103-105), and T1 post-contrast (106) axial acquisitions.  
 
Frontal horn dimensions have been expressed as a ratio of skull diameter, rather than as 
an absolute measurement. Martola et al expressed bifrontal ratio, by dividing FHW by 
transverse skull width at the same line along which FHW was assessed.(103, 105) 
Another study measured frontal horn ratio, by dividing FHW by transverse skull width at 
the level of the caudate nuclei.(102) Rather than using a ratio, Butzkeuvan et al 
normalized for the transverse skull width at the level of the rostral horns.(107)  
 
One may postulate that disparate measurements may result from CSF-bright versus CSF-
dark sequences, however this has not been investigated.  To date, linear measurement of 
the frontal horns, either as an absolute value or ratio, has not been performed on 
individuals with CIS. 
 
Third ventricular width 
Third ventricular width (TVW) is a surrogate marker for central brain atrophy.(31, 108) 
Several techniques for measurement of TVW have been utilized. Butzkeuven et al 
measured maximal width of the third ventricle on the axial T1 image in which the structure 
was most visible in its AP portion.(107) Numerous authors have used the same 
technique.(102, 109, 110) An alternate method involves drawing a line along the long axis 
of the third ventricle on the axial slice on which 3rd ventricle was most visible, with TVW 
measured as the width of a perpendicular line drawn along its midpoint.(108, 111-114) 
Mostert et al measured TVW in a cohort of 90 individuals with demyelinating disease, 62 
(68.9%) of whom technically fulfilled criteria for CIS at baseline.(110) To date, TVW has 
not been assessed in CIS-only cohorts. 
 
Intercaudate distance  
The minimum distance between the heads of the caudate nuclei on axial MRI images is 
the intercaudate distance (ICD).(102, 104, 107, 115) A similar measure, the bicaudate 
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ratio, is the ICD divided by the brain width at the same level.(105, 110, 112, 116, 117) As 
for third ventricular ratio, bicaudate ratio is considered a marker of subcortical atrophy.(31, 
108, 112, 117, 118)  Patients with established MS have demonstrated larger ICD 
compared to healthy controls (p<0.001).(107) Intercaudate ratio has also been found to 
associate with whole brain volume in those with MS.(108, 119) To date, neither ICD nor 
intercaudate ratio has been assessed in CIS-only cohorts.  
 
Other linear measures 
Linear measures of brain atrophy which have been less frequently investigated in patients 
with demyelinating disease include: 
• Interuncal distance(103, 105) 
• Biuncal ratio(103, 105) 
• Evans’ ratio(106) 
• AP diameter of temporal horn(106) 
• Oblique anterior horn diameter of the lateral ventricles(106) 
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CHAPTER 3: GENERAL METHODOLOGY 
 
Subjects 
The Ausimmune Longitudinal (AusLong) Study was designed to study environmental, 
genetic and personal risk factors for the onset and progression of MS(120) in a large 
cohort of patients who had initially presented with clinically isolated syndrome and been 
recruited into the multicentre Ausimmune study. Patients were eligible for the current study 
if they had sagittal MRI imaging data available at baseline and 5 year follow up.  All 
patients signed written informed consent. The study had multicentre ethics approval.  
 
Clinical and Epidemiological Data 
As a part of the AusLong and Ausimmune studies, epidemiological, clinical and MRI data 
were obtained at baseline and 5 years. Clinical data included date of symptom onset, 
EDSS, date of conversion to MS, and MS subtype at conversion.  
 
Clinical and epidemiological data were retrieved from the principal site of AusLong data 
storage, at the Menzies Research Institute, Tasmania. Sample size was limited to those 
subjects who previously consented to ongoing participation in the AusLong and AusLong II 
studies, and who had sufficient serial MRI scan data for analysis. Baseline and 5-year 
clinical, epidemiological and MRI data was obtained from a total 283 participants.  
 
MRI Acquisition 
MRI data collected as part of the multicentre Ausimmune and AusLong Studies was 
used.(120) For Ausimmune, the baseline MRI was a clinical scan obtained using the MRI 
protocol of choice of the referring centre.(120) As such, there was heterogeneity in 
sequences obtained at baseline. Patients recruited into the subsequent AusLong study 
were scanned according to a defined study protocol which included a sagittal FLAIR 
sequence.(121) Those participants whose MRI studies were inadequate (i.e. lacking the 
requisite sequences) to permit the atrophy measures being performed at either time point 
were subsequently excluded.  Participant data was not excluded on the basis of scanner 
manufacturer or software. 
 
MRI Analysis 
Two-dimensional atrophy measures were performed on baseline and 5-year MRI studies. 
Scanned copies of printed MRI films were excluded, due to difficulty in reliably estimating 
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distance on scanned hard-copy films. All measurements were performed on OsiriX DICOM 
Viewer (Pixme Sarl, Bernex, Switzerland), on Mac OS (Extended) (Apple Inc., Cupertino, 
CA, USA), on monitors with resolution 1920 x 1080. 
 
Corpus Callosum Area  
Midsagittal corpus callosum area (CCA) was performed on those subjects with sagittal 
sequences performed at both baseline and 5-year follow-up.(122-131) The FLAIR 
sequence was used if available (as this was part of the AusLong MRI protocol). Where 
FLAIR sagittal was not performed at baseline, a sagittal T1 sequence was used.  The best 
midsagittal image was selected; landmarks used to identify the best midsagittal image 
included vessels within the sagittal fissure, the great cerebral vein, and the cerebral 
aqueduct. If not all of the above features could be identified, the ‘closest fit’ image was 
selected.  
 
Image quality was assessed by two observers (CO, AC) with each image being assigned 
‘poor’, ‘fair’ or ‘good’. Data from participants whose scans were of ‘poor’ image quality at 
both baseline and five-year analysis were excluded (n = 11); data from participants with at 
least one study assigned ‘fair’ or ‘good’ was retained.  
 
Midline sagittal corpus callosum area (CCA) was outlined manually three times using a 
tablet digitiser (Wacom Technology Corporation, Vancouver, WA, USA) The fornix was not 
included. If required, the corpus callosum outline was extrapolated from the adjacent 
curvature. Any lesions within the corpus callosum were included in the outline. Three 
outlines were made, with the mean of the three values to be taken as the CCA (Figure 1). 
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Figure 1 Semi-automated outline of midsagittal CCA. Abbreviation: CCA = corpus callosum area. 
 
Intracranial area 
Due to insufficient numbers of subjects having three-dimensional MRI sequences at both 
time points (n = 7), two-dimensional measures were used for normalisation for skull size. 
Midsagittal intracranial area was used for normalisation of corpus callosum area; this 
method has previously been validated.(125) The internal skull surface area was traced on 
the same image used for CCA. The inferior margin of the skull was taken as a line directed 
posterior from the posterior arch of C1.  
 
Frontal Horn Width  
The most caudal T1-weighted slice on which the frontal horns appear to reach maximal 
width was selected. The maximal distance between the lateral margins of the frontal horns 
of the lateral ventricles was measured (Figure 2).(103) If two consecutive slices appeared 
to have the same width, the most caudal was chosen. If the ventricles were grossly dilated 
with the caudate nucleus not visible at the widest point, the next most caudal slice that 
demonstrated the caudate nucleus was selected. To confirm whether narrow-appearing 
ventricles contained cerebrospinal fluid, the T2 sequence (if available) was reviewed. 
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Intercaudate Distance  
On the same slice as FHW was assessed, the minimum distance between the medial 
borders of the head of the caudate nuclei was measured (Figure 2).(107) 
 
Transverse Skull Diameter  
Transverse skull diameter was used to normalisation for skull size (for the linear 
measures); this method has previously been validated.(107) On the same slice as the 
FHW and ICD, the minimum distance separating the inner tables of the skull at the level of 
the most rostral portion of the frontal horns (Figure 2).  
 
 
Figure 2 Typical T1-weighted axial slice selected for linear atrophy measurements. Abbreviations: 
FHW = frontal horn width; TSD = transverse skull diameter; ICD = intercaudate distance. 
 
FH
W
ICD 
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Third Ventricular Width 
The T1-weighted axial slice that best demonstrated the third ventricle in its antero-
posterior extent was selected. If the third ventricle were equally visible on multiple slices, 
the most caudal was selected. The transverse width of the third ventricle at its widest point 
was measured (Figure 3).(107) 
 
 
Figure 3 Typical T1-weighted axial slice selected for linear atrophy measurements; immediate caudal 
slice to Figure 1. Abbreviation: TVW = third ventricular width. 
 
 
 
 
TVW 
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Reliability Assessment 
A subset of 30 MRI studies was selected at random. To assess intra-rater reliability, a 
single observer (CO) performed all measurements on each MRI on two occasions, 
separated by 7 days. 
 
To assess the inter-rater reliability, two independent observers (CO & JO) repeated the 
measures on the same group of 30 randomly selected subjects. Each observer was 
blinded to the results of the other.  
 
As CCA measures were performed on either FLAIR or T2 (if FLAIR unavailable) 
sequences, the reliability of CCA measurement on different sequences was assessed. 
CCA measurement was performed by a single observer (CO) on 20 randomly selected 
subjects having both FLAIR and T2 sagittal sequences.  
 
Validation of 2D CCA measurement using 3D data 
A validation study was performed to test the association between automatically derived 
CCA, ICA, corpus callosum volume and intracranial volume within a healthy population 
using scans from a separate cohort of healthy people acquired as part of the Australian 
Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL).(132) Automatically 
extracted midsagittal CCA and ICA were correlated with corpus callosum volume and 
intracranial volume. T1-weighted volumes were prepared for processing and segmentation 
using the MILXView neuroimaging platform (AEHRC, Brisbane, QLD, Australia), which 
aligns MRI data to Montreal Neurological Institute and Hospital (MNI) coordinates prior to 
mid-slice extraction and midsagittal measurement.(133)  
 
Clinical measures 
Conversion to CDMS was defined as the occurrence of two or more clinical demyelinating 
episodes, thus satisfying the diagnostic requirements of dissemination in space and time, 
or a single episode plus paraclinical evidence, as per the 2005 McDonald criteria (a 
minority of cases were diagnosed following MRI based on these latter criteria 
(n=20)).(134) Conversion to CDMS was reported at annual review and crosschecked 
against neurological records. A relapse was defined according to the 2001 McDonald 
Criteria(135) as the acute or subacute appearance or reappearance of a neurological 
abnormality (lasting at least 24 hours) in the absence of other potential explanatory 
factors. Relapses were reported at annual review; only relapses that were diagnosed and 
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verified by a neurologist were included in this analysis. Disability was assessed at follow-
up by the Kurtzke Expanded Disability Status Scale (EDSS). 
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CHAPTER 4: STUDY 1 
 
Midsagittal corpus callosum area and conversion to multiple sclerosis after 
clinically isolated syndrome: a multicentre Australian cohort study 
 
Introduction   
Patients with longstanding multiple sclerosis (MS) demonstrate neuronal loss and cerebral 
atrophy, with reduced brain volume being regarded as a surrogate marker for 
neurodegeneration.(1-3) The pathophysiological processes underpinning cerebral atrophy 
are not limited to those that occur during the acute demyelinating episode, as cellular 
inflammation and neuronal loss persist long after the acute relapse is complete.(46) 
Whether cerebral atrophy is detectable at the time of the earliest demyelinating event has 
not yet been clearly elucidated.(136)  
 
The corpus callosum, as the largest bundle of white matter tracts in the brain, is a region of 
particular interest in multiple sclerosis. Pathology within the corpus callosum may reflect 
both local and distant processes, through demyelination, inflammation and secondary 
Wallerian degeneration.(129, 137) Unlike many other brain regions, however, the corpus 
callosum is not well suited to volumetric analysis, due to inherent difficulty in defining its 
lateral margins.(122, 125) Fortuitously, midsagittal corpus callosum area (CCA) is a 
validated method of quantifying atrophy of the corpus callosum.(122-131) 
 
The aim of the present study was to determine whether CCA at first demyelinating event is 
a marker of disease progression at five years, including conversion to MS, clinical relapses 
and disability, and whether CCA at 5 years differs between patients who convert to MS 
and those who do not. 
 
Methods 
Statistical analysis 
The distribution of covariates by study site was evaluated by Chi-square test for 
categorical variables, and t-test for continuous terms. Associations between MRI 
measures and clinical course were analysed by linear regression for continuous outcomes, 
and log-binomial regression for dichotomous outcomes. Interactions were assessed by the 
creation of a product term between the two parameters being evaluated, with the 
significance of the product term denoting the significance of the interaction. Linearity of 
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effects was evaluated by categorising the independent variable in quartiles, and testing for 
trend across these categories. Cronbach’s alpha was used for the reliability studies. A 
one-way random effects model, single measures, was used for the intra-rater reliability, 
and a two-way random effects model, single measures, for the inter-rater reliability. 
Spearman’s correlation was used for the validation study. 
 
Change in parameters between baseline and five-year review were calculated as follows:  
• change in CCA (ΔCCA) was calculated as 5-year CCA minus baseline CCA; 
absolute annualised change in CCA was calculated by dividing this value by the time in 
years from baseline to 5-year review; and annualised percentage change by calculating 
the annualised change as a percent of baseline CCA.    
• change in disability was taken as the 5-year EDSS, under the assumption that the 
EDSS on the day before the first event was 0; annualised change in disability was 
calculated by dividing this value by the duration between the day before the first 
demyelinating event and the 5-year review to yield the annualised percentage change. 
• annualised relapse rate was calculated by dividing the total number of relapses by 
the time in years from baseline to 5-year review. The first relapse is considered to define 
the start point for MS disease diagnosis since the initial CIS presentation was not included 
in calculations; this is considered a consistent bias that is unlikely to affect study 
outcomes. 
 
All multivariable models include age, sex and study site. Statistical analyses were 
performed using Stata Version 12.1 (StataCorp, College Station, TX, USA). 
 
Results 
Cohort Characteristics 
Cohort characteristics are presented in Table 1.  Of the 282 participants with a first clinical 
diagnosis of CNS demyelination recruited into the Ausimmune Study, 143 had complete 
imaging and clinical data available from baseline and 5 year review. These 143 patients 
formed the study group. The cohort included 113 females (age 34.13±9.39 years), and 30 
males (age 33.11±8.31 years). The 143 participants resided in four Australian states: 
Queensland (n=32), New South Wales (n=24), Victoria (n=49) and Tasmania (n=38). 
There was no significant variation in sex ratio between sites (p=0.22).  
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Table 1 Cohort characteristics for 143 persons with MRI data at baseline and 5-year review.  
 
All persons Males Females 
Converters 
(n=110) 
Non-
converters 
(n=33) 
Baseline CCA (cm2)  6.63 (1.01) 7.07 (1.09) 6.51 (0.96) 6.54 (1.02) 6.92 (0.91) 
Follow-up CCA (cm2) 6.34 (0.98) 6.77 (0.76) 6.23 (9.540 6.22 (0.98) 6.74 (0.89) 
Baseline ICA (cm2) 157.79 (10.95) 167.23 
(10.95) 
155.29 (9.49) 157.24 
(11.25) 
159.62 
(9.81) 
Total ΔCCA (%) -3.37 (13.59) -2.69 (14.27) -3.56 (13.47) -3.87 (13.78) -0.18 (0.88) 
Mean annualised ΔCCA (%) -0.57 (2.91) -0.64 (2.79) -0.54 (2.96) -0.64 (3.05) -0.32 (2.42) 
Results presented as mean (SD). Abbreviations: CCA = corpus callosum area; ICA = intracranial area. 
 
Validation studies 
For the CCA measurement technique, intra-rater reliability was 0.84 (p<0.001) and inter-
rater reliability was 0.93 (p<0.001). CCA measurements on T1 versus FLAIR images 
showed a high intraclass correlation of 0.97 (95% CI: 0.94, 0.99).  
 
Correlation between automatically derived CCA and CCV was performed in a separate, 
healthy cohort. Positive correlation was found between automatically derived CCA and 
CCV (r=0.78), in addition to between automatically derived ICA and ICV (r=0.88). 
 
Corpus callosum area (CCA) 
Mean baseline CCA was 6.63 (SD 1.01) cm2. There was no association between patient 
age and baseline CCA (p=0.98). Baseline CCA was significantly smaller among females 
than males (β: -0.57 (95% CI: -0.97, -0.17) cm2, p=0.006), as was baseline intracranial 
area (ICA) (β: -11.94 (95% CI: -15.93, -7.95) cm2, p<0.001). Similar differences by sex 
were seen for five-year CCA and ICA. Mean time between MRI scans was 5.48 (SD 1.05) 
years.  
 
Mean CCA at 5-year follow-up was 6.34 (SD 0.98) cm2 (Figure 4). Mean total ΔCCA 
was -0.28 (SD 0.91) cm2, or -3.37% (SD 13.59); this equated to mean annual ΔCCA 
of -0.57% (SD 2.91). Mean relapse number by follow-up was 2.56 (SD 3.48), with a mean 
annualised relapse rate of 0.30 (SD: 0.42) per year.  
 
Relationships between MRI and clinical parameters 
Associations between baseline CCA and subsequent MRI and clinical variables are 
presented in Table 2. Baseline CCA was a significant predictor of five-year CCA; five-year 
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CCA increased by ~0.6cm2 for every 1cm2 increase in baseline CCA. The size of this 
effect increased following adjustment (Figure 4). Greater baseline CCA was also predictive 
of a greater reduction in CCA by follow-up, in terms of absolute annualised change (β: -
0.09 (95% CI: -0.12, -0.06), p<0.001) and annualised percentage change (β: -1.19 (95% 
CI: -1.63, -0.76), p<0.001).  
 
 
 
 
Baseline CCA was associated with risk of subsequent conversion to CDMS, however, this 
did not persist following adjustment for age. There was no association between baseline 
CCA and progression in disability scores. Higher baseline CCA was associated with a 
significantly increased relapse rate; however, this association was strongly influenced by 
an individual with a very high relapse rate (3.62 relapses/yr). Excluding the outlier 
abrogated this association (IRR: 1.03 (95% CI: 0.93, 1.15), p=0.58).  
 
Patients who were shown to have converted to MS at five-year review had a significantly 
reduced CCA (-0.52, p=0.007) at 5 years (Table 3). Higher annual relapse rate was 
predictive of a smaller CCA at five-year review (p=0.001) and a greater rate of CCA 
reduction (p=0.024); however, these associations were lost following exclusion of data 
from the outlier with very high relapse rate (p=0.12). Greater EDSS at five-year review was 
significantly associated with a greater rate of CCA reduction, and smaller CCA at follow-
up. 
 
Figure 4 Association between baseline and 5-year CCA.  
Results presented as geometric mean (95% CI) of five year CCA, adjusted for age, sex, site and baseline 
CCA. CCA = corpus callosum area. 
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Table 3 Clinical course parameters as predictors of 5-year CCA and annualised change in CCA. 
 Five-year CCA Annualised Change in CCA 
 Univariable Adjusteda Univariable Adjusteda 
Conversion to 
CDMS by 5-yr  
-0.52 (-0.90, -0.15) 
p=0.007 
-0.56 (-0.93, -0.19) 
p=0.003 
-0.02 (-0.10, 0.06) 
p=0.60 
-0.07 (-0.14, -0.01) 
p=0.035 
     
Relapse rate, FDE 
to 5-yr review 
-0.55 (-0.94, -0.17) 
p=0.005 
-0.45 (-0.83, -0.07) 
p=0.021 
-0.02 (-0.06, 0.02) 
p=0.42 
-0.12 (-0.19, -0.05) 
p=0.001 
0 – 0.10 
>0.10 – 0.14 
>0.14 – 0.44 
>0.44 – 3.62 
Trend: 
6.68 (6.36, 7.00) 
-0.42 (-0.90, 0.06) 
-0.22 (-0.65, 0.22) 
-0.66 (-1.11, -0.20) 
p=0.016 
6.65 (6.34, 6.96) 
-0.20 (-0.67, 0.27) 
-0.29 (-0.71, 0.12) 
-0.61 (-1.08, -0.15) 
p=0.010 
-0.01 (-0.08, 0.05) 
-0.08 (-0.17, 0.03) 
-0.01 (-0.10, 0.08) 
-0.10 (-0.19, -0.00) 
p=0.14 
-0.01 (-0.06, 0.05) 
-0.06 (-0.15, 0.02) 
-0.02 (-0.10, 0.06) 
-0.12 (-0.21, -0.04) 
p=0.024 
5-yr EDSS -0.18 (-0.28, -0.08) 
p=0.001 
-0.19 (-0.28, -0.09) 
p<0.001 
-0.01 (-0.03, 0.01) 
p=0.24 
-0.02 (-0.04, -0.00) 
p=0.023 
0 – 1 
>1 – 1.5 
>1.5 – 2.5 
>2.5 – 7.0 
Trend: 
6.68 (6.41, 6.95) 
-0.25 (-0.70, 0.20) 
-0.50 (-0.92, -0.09) 
-0.78 (-1.22, -0.34) 
p<0.001 
6.74 (6.49, 7.00) 
-0.42 (-0.85, 0.02) 
-0.58 (-0.97, -0.19) 
-0.84 (-1.26, -0.41) 
p<0.001 
-0.06 (-0.12, -0.01) 
+0.07 (-0.02, 0.16) 
+0.03 (-0.05, 0.12) 
-0.06 (-0.15, 0.04) 
p=0.37 
-0.03 (-0.08, 0.02) 
+0.00 (-0.08, 0.08) 
-0.01 (-0.08, 0.06) 
-0.09 (-0.16, -0.01) 
p=0.046 
Annualised 
changed in EDSS 
-0.11 (-0.66, 0.45) 
p=0.71 
-0.23 (-0.79, 0.33) 
p=0.41 
-0.07 (-0.18, 0.04) 
p=0.18 
-0.07 (-0.17, 0.03) 
p=0.14 
-1.30, -0.19 
>-0.19, 0 
>0, 0.20 
>0.20, 1.18 
Trend: 
6.55 (6.19, 6.91) 
-0.18 (-0.65, 0.29) 
+0.33 (-0.28, 0.95) 
-0.41 (-0.91, 0.09) 
p=0.23 
6.64 (6.29, 6.98) 
-0.29 (-0.75, 0.17) 
+0.34 (-0.23 ,0.91) 
-0.58 (-1.07, -0.10) 
p=0.10 
-0.04 (-0.11, 0.03) 
+0.03 (-0.06, 0.12) 
+0.11 (-0.01, 0.23) 
-0.04 (-0.13, 0.06) 
p=0.56 
-0.03 (-0.09, 0.03) 
+0.03 (-0.06, 0.11) 
+0.11 (0.01, 0.22) 
-0.06 (-0.15, 0.03) 
p=0.28 
Abbreviations: CCA = Corpus callosum area; FDE = First demyelinating event; EDSS = Expanded Disability Status 
Scale. 
Analyses predicting continuous outcomes (5-year CCA, change in CCA, change in EDSS) evaluated by linear 
regression, presented as the geometric mean (95% CI) of the reference and coefficients relative to the reference 
(95% CI) for subsequent levels. Analyses predicting dichotomous outcomes (conversion to CDMS) evaluated by 
log-binominal regression, presented as prevalence ratios (95% CI) relative to the reference. Analyses predicting 
count-based outcomes (relapse rate) evaluated by Poisson regression, presented as incidence rate ratios (95% CI) 
relative to the reference.  
aAdjusted for age, sex, study site and 5-year intracranial area. Analyses of disability also adjusted for whether 
participants were having a relapse at the time of their 5-year disability measure.  
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Discussion  
In current practice, MRI reporting in individuals with CIS and MS is based upon the 
subjective, semi-quantitative assessment of T2 hyperintense and T1 hypointense lesions 
within the cerebrum and spinal cord.(135) However, there is argument for more 
standardised, quantitative MRI data.(138) While software for volumetric analysis is 
becoming more widely available, these tools remain generally inaccessible to the 
practicing radiologist. This study was aimed to explore the potential utility of two-
dimensional cerebral atrophy measures in patients presenting with CIS. 
 
In this cohort of Australian individuals with CIS, although baseline CCA was associated 
with annual reduction in CCA, it was not associated with conversion to MS, nor other 
markers of clinical course such as disability progression. Participants who converted to 
CDMS demonstrated greater rates of corpus callosum atrophy, and a smaller mean CCA 
at five-year review. In addition, greater rates of CCA reduction were associated with 
annualised relapse.  
 
Few studies have addressed whether corpus callosum atrophy precedes the clinical 
diagnosis of MS. In our cohort, after adjusting for demographics and baseline ICA, those 
who converted to CDMS demonstrated a significantly greater rate of corpus callosum 
atrophy by five-year review.  In contrast, a 2012 study found no significant difference in 
CCA between MS converters at 2 years compared to non-converters.(34) These 
conflicting results may be attributable to varying rates of callosal atrophy following CIS. In 
their longitudinal study, Kalincik et al performed serial MRIs at 3-6 month intervals from 
initial CIS presentation. They concluded that the rate of callosal atrophy was inconstant 
over time, with early reduction in CCA being most strongly associated with conversion to 
MS by two years (being adjusted for age, gender and changes in treatment).(34) As CCA 
was measured at only two timepoints in this study, we cannot define when greatest 
change in CCA occurred, nor conclude whether CCA change is a linear process. 
 
An important finding from this study was that a higher relapse rate was predictive of a 
greater annualised change in CCA, and smaller CCA at five-year follow-up. This supports 
the concept that in earliest MS, cellular processes leading to brain atrophy are 
exacerbated by acute inflammatory activity (i.e. relapses).(46) These findings are in 
concordance with those of previous authors.(34)  
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MRI volumetric analysis has previously provided insight into the associations between 
cerebral atrophy and disability in patients with CIS.(139) However, MRI volumetric analysis 
is complex, time-consuming, and reliant upon specialised MRI sequences usually reserved 
for research protocols.(130) In contrast, CCA is a simple, robust method for quantification 
of callosal atrophy which may be easily incorporated into diagnostic protocols by the 
everyday radiologist.(130) Interestingly, CCA measurement has recently been 
demonstrated to outperform several volumetric measures in predicting physical and 
cognitive impairment in patients with established MS.(3, 130)  
 
Similarly to MRI brain volumetrics, two-dimensional cerebral atrophy measures may be 
affected by transient physiological and pathological factors, such as oedema and 
gliosis.(125) Random measurement error is also a potential source of error. In our cohort, 
56 participants demonstrated an increased CCA over the five-year period, with mean CCA 
increase within this subgroup being 0.63 (SD 0.42) cm2. This may be explained by: 
transient pathological phenomena, scanner heterogeneity, additional/alternative 
pathological processes or operator error.(140) 
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CHAPTER 5: STUDY 2 
 
Linear measures of brain atrophy on axial MRI in individuals with CIS 
 
Introduction 
Multiple sclerosis (MS) is a chronic autoimmune disease of CNS demyelination, of which 
neurodegeneration and subsequent cerebral atrophy plays a key role in the 
pathogenesis.(1-3) Whether cerebral atrophy is detectable at the time of the earliest 
demyelinating event - known as the clinically isolated syndrome (CIS) - has not yet been 
clearly elucidated.(136) 
 
MRI volumetric measurements are generally considered inaccessible to the everyday 
clinician, requiring lengthy acquisition sequences usually reserved for research purposes, 
in addition to complex post-processing analysis, which requires both the expertise and the 
time taken for image processing.(130) Linear measures of cerebral atrophy may be a 
viable alternative to three-dimensional volumetric analysis, through their rapid applicability 
on MRI protocols used in standard clinical practice.(107) 
 
In this study we aim to assess the development of brain atrophy in patients presenting with 
CIS, using serial linear measurements as surrogates of cerebral volume. In addition, we 
will evaluate the relationships of these measures with clinical outcome variables, including 
conversion to MS, annualised relapse rate and disability. 
 
Methods 
Statistical analysis 
The distribution of covariates by study sites was evaluated by ANOVA for parametric 
variables, and Kruskal-Wallis test for nonparametric variables. Sex differences were 
assessed by t-test for continuous terms, and Mann-Whitney U-test for nonparametric 
variables. Associations between MRI measures and clinical course were assessed by 
univariate analysis for continuous variables, and binary logistic regression for dichotomous 
outcomes. Cronbach’s alpha was used for the reliability studies. A one-way random effects 
model, single measures, was used for the intra-rater reliability, and a two-way random 
effects model, single measures, for the inter-rater reliability.  All statistical analyses were 
performed using SPSS for Mac OS Version 20.0 (SPSS Inc, Chicago, Ill, USA). 
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Results  
Reliability Study 
Intra-rater reliability was satisfactory for all linear measures: FHW ICC = 0.927, p<0.001; 
ICD ICC = 0.771, p < 0.001; TSD ICC 0.771, p < 0.001, TVW ICC 0.891, p < 0.001. Inter-
rater reliability was also satisfactory for all linear measures: FHW ICC = 0.809, p < 0.001; 
ICD ICC 0.902, p < 0.001; TVW ICC 0.03, p<0.001. 
 
Cohort Characteristics 
Cohort characteristics at baseline are presented in Table 1. Of the 282 participants with 
CIS recruited into the Ausimmune Study, 154 had complete imaging and clinical data 
available from baseline and five-year review, and were included in the analysis. Mean age 
at baseline was 34.3±9.4 years. Participants resided in Queensland (n = 34), New South 
Wales (n = 25), Victoria (n = 54) and Tasmania (n = 41). The cohort included 35 males 
(mean age 33.83 ±9.56), and 119 females (mean age 34.43 ±9.40). Study sites did not 
differ significantly in any of the baseline variables. There was significant sex difference in 
baseline FHW (p < 0.001); as such, sex was used as a control variable for analyses. 
 
Table 4 Cohort characteristics for 154 participants at baseline.  
 25th Centile Median 75th Centile 
Baseline FHW (cm) 3.04 3.22 3.42 
Baseline ICD (cm) 0.87 1.02 1.19 
Baseline TSD (cm) 10.77 11.09 11.41 
Baseline TVW (cm) 0.27 0.38 0.50 
Abbreviations: FHW = frontal horn width; ICD = intercaudate distance; TSD = transverse skull diameter; 
TVW = third ventricular width. 
 
Cohort characteristics at five-year review are presented in Table 2. The median time 
interval between MRI acquisitions was 5.5 years (IQR 5.10-6.01).  
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Table 5 Cohort characteristics at five years.  
 25th Centile Median 75th Centile 
Five-year FHW (cm) 3.04 3.22 3.43 
Five-year ICD (cm) 0.93 1.10 1.30 
Five-year TVW (cm) 0.33 0.45 0.53 
Relapse rate (annual) 0.00 0.11 0.25 
Change in EDSS 0.00 0.21 0.35 
Abbreviations: FHW = frontal horn width; ICD = intercaudate distance; TSD = transverse skull diameter; 
TVW = third ventricular width. 
 
MS converters versus non-converters 
By five-year review, 124 out of 154 CIS patients converted to clinically definite MS. To 
compare MRI variables between those participants who converted to MS with those who 
did not, we normalised for skull width by dividing each of the linear measures by 
transverse skull diameter to produce a ratio. The following ratios were obtained: frontal 
horn ratio (FHR) = FHW/TSD; intercaudate ratio (ICR) = ICD/TSD; and third ventricular 
ratio (TVR) = TVW/TSD. None of these measures differed significantly between converters 
and non-converters at either baseline or five-years.  
 
Change in EDSS (t = 6.27, p < 0.001) and annualised relapse rate (t = 4.13, p < 0.001) 
both differentiated significantly between converters and non-converters. 
 
Associations between MRI and clinical variables 
Partial correlations were performed to assess the relationship between MRI and clinical 
variables, including annualised relapse rate and change in EDSS, controlling for sex 
(Table 6). Ratios of each absolute linear measure were used to account for head size.  
Change in EDSS significantly correlated with both five-year ICR (r = 0.166, p = 0.41) and 
five-year TVR (r = 0.226, p = 0.05). None of the baseline MRI variables correlated with the 
follow-up clinical variables. 
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Table 6 Associations between MRI and clinical variables 
 Change in EDSS Annualised Relapse Rate 
Baseline FHR 0.009 (p = 0.913) -0.110 (p = 0.175) 
Baseline ICR 0.101 (p = 0.213) -0.019 (p = 0.813) 
Baseline TVR 0.152 (p = 0.061) -0.011 (p = 0.890) 
Five-year FHR 0.023 (p = 0.780) -0.049 (p = 0.552) 
Five-year ICR 0.166 (p = 0.041)* 0.008 (p = 0.921) 
Five-year TVR 0.226 (p = 0.005)* 0.069 (p = 0.394) 
All analyses controlled for sex.  
 
Univariate regression was performed, controlling for sex, with each of the baseline linear 
measures (as a ratio) inserted singularly into the model in turn, and as a group. None of 
the baseline linear measures was a significant predictor of relapse rate or change in 
EDSS. 
 
Discussion  
In this study, we set out to investigate whether CIS patients who converted to MS by five-
year review demonstrated change in several one-dimensional linear measures of brain 
size. None of FHR, ICR or TVR was found to be significantly different in those subjects 
who converted to MS by five years, compared to those who did not convert. Further, 
among those subjects who converted to MS, there was no significant difference between 
their baseline and five-year linear measures. In their 2008 study, Butzkeuven et al found 
that ICD and TVW differentiated between MS patients and healthy controls(107), a finding 
that appears discordant with our own. As all our study participants experienced at least 
one neurological event, it may be postulated that linear measures were altered from a 
‘normal’ baseline within the total cohort. Future introduction of a healthy cohort may be 
warranted to further investigate this proposition.  
 
Although none of the baseline linear atrophy measures was associated with clinical 
outcome variables, we demonstrated a significant correlation between change in EDSS 
and both five-year ICR and TVR. Third ventricular width is considered a surrogate marker 
for central atrophy(31, 108), and intercaudate distance a surrogate for subcortical 
atrophy.(141) Several studies have demonstrated a positive correlation between ICR and 
EDSS in participants with established MS.(107, 119, 142) Associations between TVR and 
disability scores have been less consistent. In a recent study of 32 patients with MS, 
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Radomski et al found a positive correlation between TVR and EDSS.(102) While a more 
sizeable Australian study led by Butzkeuven found no such association, they did find that 
TVW differentiated MS patients from healthy controls.(107) To date, no study has 
demonstrated any significant association between TVR nor ICR and disability in individuals 
presenting with CIS.  
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CHAPTER 6: CONCLUSION 
 
In current practice, reporting of MRI studies of patients with CIS and MS is based upon the 
semi-quantitative assessment of white matter lesions within the brain and spinal cord. 
Given the subjective nature of such assessment, there is argument for a more 
standardised, quantitative approach to MRI analysis. Until such time as automated 
volumetric analytical software is a standard inclusion in MRI software packages, two-
dimensional measurements may provide some utility in the evaluation of cerebral atrophy 
in individuals presenting with CIS. 
  
This study represents the largest cohort of Australians followed longitudinally from CIS 
presentation. Study participants who converted to MS by five-year review demonstrated 
smaller CCA compared to those who did not convert. This finding suggests an association 
between brain atrophy and disease morbidity occurring within the first five years from CIS 
presentation. Another interesting finding was that five-year intercaudate ratio and third 
ventricular ratio significantly correlated with change in disability. Pertaining to the research 
question, however, none of the baseline MRI measures was predictive of conversion to 
MS by five years. 
 
This study contains several limitations of particular note. Due to its multi-centre design, 
there was unavoidable heterogeneity in MRI field strength and sequences, and time 
between MRI examinations; prolonged time to follow-up is likely to counter this potential 
source of error. As a consequence of the retrospective study design and absence of a 
clearly defined MRI protocol at baseline, volumetric analyses were unable to be 
performed, resulting in the absence of a three-dimensional measure for inclusion as a 
‘gold-standard’ comparative measure. The use of pharmacological treatments was not 
included as a study variable; while this may be a potential source of bias, it is noted that 
cerebral atrophy measures may also be affected by several transient physiological and 
pathological factors, including oedema and gliosis, which may counter this effect. Clinical 
outcome variables were assessed retrospectively through annual patient assessment and 
review of clinical records. Given the study’s multi-centre design and large cohort size, 
retrospective analysis was the only feasible option. Finally, due to missing/inadequate MRI 
data, analysis was restricted to a subsample of cases from the Ausimmune Study, with 
varied site retention being a potential source of bias. However, with retention rate in the 
Ausimmune/AusLong Study being 84.6%, this effect is likely to be minimal. 
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Future directions include the inclusion of T2 lesion number and lesion volume as a 
comparative variable, as well as the addition of an age- and sex-matched control group to 
assess the change in two- and three-dimensional atrophy measures within a healthy aging 
population. Finally, a more prolonged longitudinal assessment to 10 years would produce 
more statistically robust findings in the assessing utility of two-dimensional atrophy 
measures in predicting long-term disease morbidity. 
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APPENDICES 
 
Appendix 1  
 
Hyperlink to published literature review:  
http://www.ncbi.nlm.nih.gov/pubmed/24831592 
 
Hyperlink to published study 1: 
https://www.ncbi.nlm.nih.gov/pubmed/27995735  
 
Appendix 2 
 
AusLong MRI protocol 
 
• Localiser centered on anterior-posterior callosal line 
• Axial FSE PD/T2 from foramen magnum to vertex with no gap, in plane resolution 
1mm2 or better, slice thickness 5mm or better 
• Axial DWI/ADC 5mm 
• Axial T1 from foramen magnum to vertex with no gap, in plane resolution 1mm2 or 
better, slice thickness 5mm or better 
• Give IV gadolinium contrast at 0.1mmol/kg (0.2mls/kg) 
• Sagittal FLAIR centered on midline, in plane resolution 1mm2 or better, slice 
thickness 4mm 
• Axial T1 from foramen magnum to vertex with no gap, in plane resolution 1mm2 or 
better, slice thickness 5mm or better 
• 3D T1w MPRAGE or equivalent with 1mm3 or less resolution 
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